Dr. Goldenheim joined the NeuroPhage Board of Directors in March 2010. Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies including Alinea, Promedior, and Hydra Biosciences. He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Paul also serves on the board of directors of The Big Apple Circus. Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He received his A.B. from Harvard College magna cum laude with highest honors in biochemical sciences and his M.D. from Harvard Medical School.